U臒ur 脰zkerim路 @UOzkerim 路 X路路 1 day agoScore70
Body 路 original
馃毃 Another important Phase III trial at #ESMO26!
#SAFFRON: Osimertinib + savolitinib vs chemotherapy in EGFR-mutant, MET-high NSCLC after osimertinib.
馃搳 PFS: 7.6 vs 5.4 months
馃搳 OS: 17.8 vs 12.9 months
Both PFS and OS significantly improved!
A promising new targeted treatment option, highlighting the importance of biomarker testing after progression.
#LungCancer
@OncoAlert @StephenVLiu @GlopesMd @ManuelDomine @weoncologists @OpenMedKate
21 views 路 0 likes 路 0 reposts 路 0 replies
Source: U臒ur 脰zkerim 路 x.com